Does Polatuzumab Improve Outcomes In DLBCL Patients
Julie Vose, MD Professor Internal Medicine Division of Oncology & Hematology University of Nebraska Medical Center, discusses Does Polatuzumab Improve Outcomes In DLBCL Patients. At The 60th ASH Annua...
Author: obr
Added: 01/14/2019 (Source: Oncology Tube)
Source: Oncology Tube - January 14, 2019 Category: Cancer & Oncology Source Type: podcasts
Differences Between B-Cell And T-Cell Lymphomas
Lorenz Trumper, MD Professor of Internal Medicine and Chairman of the Department of Hematology and Oncology, Georg August University of Gttingen discusses Differences Between B-Cell And T-Cell Lympho...
Author: obr
Added: 01/13/2019 (Source: Oncology Tube)
Source: Oncology Tube - January 14, 2019 Category: Cancer & Oncology Source Type: podcasts
Are CAR-T Therapies Showing Impressive Results In Lymphoma
Julie Vose, MD Professor, Internal Medicine Division of Oncology & Hematology University of Nebraska Medical Center discusses Are CAR-T Therapies Showing Impressive Results In Lymphoma. At The 60th AS...
Author: obr
Added: 01/13/2019 (Source: Oncology Tube)
Source: Oncology Tube - January 14, 2019 Category: Cancer & Oncology Source Type: podcasts
Results Of MM014 Study
David Siegel, MD Hematologist/Oncologist, Hackensack University Medical Center, John Theurer Cancer Center Discusses Results Of MM014 Study. At The 60th ASH Annual Meeting on Dec 1, 2018.
Author: obr
Added: 01/12/2019 (Source: Oncology Tube)
Source: Oncology Tube - January 12, 2019 Category: Cancer & Oncology Source Type: podcasts
CAR-T Therapies In Lymphoma Treatment Algorithms
Elizabeth Budde, MD Assistant Professor in the Department of Hematology & Hematopoietic Cell Transplantation, City of Hope Discusses CAR-T Therapies In Lymphoma Treatment Algorithms. At The 60th ASH A...
Author: obr
Added: 01/11/2019 (Source: Oncology Tube)
Source: Oncology Tube - January 12, 2019 Category: Cancer & Oncology Source Type: podcasts
Research Examining Gilteritinib In Newly Diagnosed AML
John Burke, MD Hematologist/Oncologist and Associate Chair of the US Oncology Hematology Research Program, Rocky Mountain Cancer Centers Discusses Research Examining Gilteritinib In Newly Diagnosed AM...
Author: obr
Added: 01/11/2019 (Source: Oncology Tube)
Source: Oncology Tube - January 11, 2019 Category: Cancer & Oncology Source Type: podcasts
Maintenance Regimens For MM
Rafael Fonseca, MD Hematologist, Mayo Clinic Discusses Maintenance Regimens For MM At The 60th ASH Annual Meeting on Dec 1, 2018.
Author: obr
Added: 01/11/2019 (Source: Oncology Tube)
Source: Oncology Tube - January 11, 2019 Category: Cancer & Oncology Source Type: podcasts
Outcomes Of The ALCYONE Trial In MM Patients
Peter Vorhees, MD Director of Outreach and Clinical Operations, Department of Hematologic Oncology and Blood Diosrders, Levine Cancer Institute Discusses Outcomes Of The ALCYONE Trial In MM Patients A...
Author: obr
Added: 01/11/2019 (Source: Oncology Tube)
Source: Oncology Tube - January 11, 2019 Category: Cancer & Oncology Source Type: podcasts
Gilteritinib For Patients With FLT3+ AML
Edward Copelan, MD Chair, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute Discusses Gilteritinib For Patients With FLT3+ AML At The 60th ASH Annual Meeting on Dec 1, 20...
Author: obr
Added: 01/11/2019 (Source: Oncology Tube)
Source: Oncology Tube - January 11, 2019 Category: Cancer & Oncology Source Type: podcasts
Lyra Trial In Newly Diagnosed MM
Habte Yimer, MD, Hematologist/Oncologist, US Oncology Research Executive Council Member, Texas Oncology Discusses Lyra Trial In Newly Diagnosed MM At The 60th ASH Annual Meeting on Dec 1, 2018.
Author: obr
Added: 01/11/2019 (Source: Oncology Tube)
Source: Oncology Tube - January 11, 2019 Category: Cancer & Oncology Source Type: podcasts
Novel Induction Regimens In PTCL
Jasmine Zain, MD Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Director, T Cell Lymphoma Program, City of Hope Discusses Novel Induction Regimens In PTCL At The 60th...
Author: obr
Added: 01/11/2019 (Source: Oncology Tube)
Source: Oncology Tube - January 11, 2019 Category: Cancer & Oncology Source Type: podcasts
MRD As A Legitimate Surrogate Marker In CLL
Carol Moreno, M.D., PhD Hematologist, University of Barcelona Discusses MRD As A Legitimate Surrogate Marker In CLL At The 60th ASH Annual Meeting on Dec 1, 2018.
Author: obr
Added: 01/11/2019 (Source: Oncology Tube)
Source: Oncology Tube - January 11, 2019 Category: Cancer & Oncology Source Type: podcasts
The Roll Of Chemotherapy In CLL
Mitchell Smith, M.D., PhD Professor of Medicine and Associate Center Director for Clinical Investigations in the Division of Hematology & Oncology and the GW Cancer Center Discusses The Roll Of Chemot...
Author: imedex
Added: 12/31/2018 (Source: Oncology Tube)
Source: Oncology Tube - December 31, 2018 Category: Cancer & Oncology Source Type: podcasts
Ibrutinib Or Chemotherapy
Mitchell Smith, M.D., PhD Professor of Medicine and Associate Center Director for Clinical Investigations in the Division of Hematology & Oncology and the GW Cancer Center Discusses Ibrutinib Or Chemo...
Author: imedex
Added: 12/31/2018 (Source: Oncology Tube)
Source: Oncology Tube - December 31, 2018 Category: Cancer & Oncology Source Type: podcasts
Should MRD Negativity Be The Goal For Every Patient
C. Ola Landgren, M.D. Chief of the Myeloma Service in the Division of Hematologic Oncology at Memorial Sloan Kettering Cancer Center Discusses Should MRD Negativity Be The Goal For Every Patient at Ly...
Author: imedex
Added: 12/31/2018 (Source: Oncology Tube)
Source: Oncology Tube - December 31, 2018 Category: Cancer & Oncology Source Type: podcasts
